Commerce on the share market opened with slight surplus supply and demand, posting mixed trade later in the day, with downward tendencies on both the Mishtanim and Karam Indices. Bank Leumi traded on outstanding turnover of close to NIS 4 million and a 2% drop, while ICL rose 1%, Teva rose slightly and Bank Hapoalim dropped 1%.
There were slight to moderate increases on the bond market in index-linked, foreign currency-linked and shekel channels.
Involvement on the part of Maof Options players, like that of foreign investors, changed the share market’s visage today. Two new shares leapt to the top of the list today, pushing Teva into third place and Koor into eighth. First place was taken by Bank Leumi, which declined 2% on NIS 4 million turnover, followed by ICL which benefited from extraordinary demand of NIS 2 million this morning rising 1% on over NIS 3 million turnover.
It should be noted that Bank Hapoalim also traded on outstanding turnover of NIS 3 million on a 1% decline, indicating a possible revival of the banking sector. On the other hand, at least in the case of Hapoalim, there is a specific reason for interest in the share: the announcement that the Fishman group, which is bidding for acquisition of the bank, had found another large strategic investor.
Clal Electronics' downslide slowed somewhat and Clal Industries instead fell 1.2% today, on significant turnover. The drop was due to reports, which were subsequently denied, that Polgat intended to join the ranks of those textile industries which were closing factories. Clal Israel itself traded on slight rises and Discount Investments fell almost 2%.
Kitan was still operating under the influence of its internal crisis and fell 7%. Tambour, apparently affected by off-floor demand, was up 6%.
On the Karam Index, trading was mixed on a downward trend. There were buyers only for Pri Haemek shares, due to a forgiveness of debt.
Notice:
The editorial board is not responsible for the accuracy of data or
advertisements published in Arena. Articles, news or reports are
not to be construed as recommendations or opinions concerning the
acquisition or sale of securities.